MitralCord
Minimally Invasive Solution for Mitral Valve Regurgitation
Company Overview
Snapshot
Founded in June 2012 by Igal Kushnir, MitralCord operated with 1–10 employees. MitralCord ceased operations in December 2019.
Business overview
MitralCord developed a minimally invasive transcatheter-transseptal solution for mitral valve regurgitation, a prevalent heart disease. The company's technology aimed to eliminate the risks associated with open-heart surgery by performing procedures on a beating heart, thereby reducing hospitalization periods and accelerating patient recovery. MitralCord focused on the Health Tech & Life Sciences sector, specifically within Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers in markets including Europe, Israel, Americas, China, Asia, and the United States.
Log in to access full profile ›Company Intelligence Q&A
- What is MitralCord's primary focus?
- MitralCord focused on developing a minimally invasive transcatheter transseptal solution for mitral valve regurgitation, aiming to improve patient outcomes by avoiding open-heart surgery.
- When was MitralCord founded?
- MitralCord was founded in June 2012 by Igal Kushnir.
- What was the operational status of MitralCord?
- MitralCord ceased operations in December 2019.
- What stage of development was MitralCord's product in?
- MitralCord's solution was well into its R&D phase, having successfully passed proof-of-concept and several preclinical animal studies.